Drug Profile
Apilimod dimesylate - OrphAI Therapeutics
Alternative Names: AIT-101; LAM 002A; LAM-002Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator LAM Therapeutics
- Developer OrphAI Therapeutics; Yale University
- Class Antidementias; Antineoplastics; Antivirals; Hydrazines; Morpholines; Pyrimidines; Small molecules
- Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PIKFYVE protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; COVID 2019 infections; Non-Hodgkin's lymphoma
- Discontinued Frontotemporal dementia
Most Recent Events
- 15 Feb 2024 Apilimod dimesylate - OrphAI Therapeutics receives Orphan Drug status for Amyotrophic lateral sclerosis in European Union
- 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics
- 28 Sep 2023 AI Therapeutics completes a phase IIa trial in Amyotrophic lateral sclerosis in USA (PO) (NCT05163886)